Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:FTLF NASDAQ:LGVN NASDAQ:PEPG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.76+14.8%$0.89$0.63▼$10.64$106.75M1.713.06 million shs1.29 million shsFTLFFitLife Brands$10.94-0.6%$9.85$8.67▼$20.98$102.74M0.0225,109 shs8,675 shsLGVNLongeveron$0.81+2.9%$0.89$0.48▼$1.80$24.95M-0.353.20 million shs63,890 shsPEPGPepGen$1.52+3.7%$1.59$1.01▼$7.80$104.79M1.931.09 million shs229,169 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma0.00%+4.59%-33.84%-51.47%-93.52%FTLFFitLife Brands0.00%+11.55%+4.86%-21.69%-21.36%LGVNLongeveron0.00%+7.21%+16.72%-11.84%-39.80%PEPGPepGen0.00%+4.26%-5.16%-72.52%+2.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.76+14.8%$0.89$0.63▼$10.64$106.75M1.713.06 million shs1.29 million shsFTLFFitLife Brands$10.94-0.6%$9.85$8.67▼$20.98$102.74M0.0225,109 shs8,675 shsLGVNLongeveron$0.81+2.9%$0.89$0.48▼$1.80$24.95M-0.353.20 million shs63,890 shsPEPGPepGen$1.52+3.7%$1.59$1.01▼$7.80$104.79M1.931.09 million shs229,169 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma0.00%+4.59%-33.84%-51.47%-93.52%FTLFFitLife Brands0.00%+11.55%+4.86%-21.69%-21.36%LGVNLongeveron0.00%+7.21%+16.72%-11.84%-39.80%PEPGPepGen0.00%+4.26%-5.16%-72.52%+2.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/AFTLFFitLife Brands 2.25Hold$21.5096.47% UpsideLGVNLongeveron 2.25Hold$5.50583.23% UpsidePEPGPepGen 2.67Moderate Buy$11.60661.15% UpsideCurrent Analyst Ratings BreakdownLatest LGVN, FTLF, PEPG, and AIFC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/4/2026FTLFFitLife Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)6/2/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/22/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026PEPGPepGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/13/2026PEPGPepGen WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$5.00 ➝ $4.005/11/2026LGVNLongeveron Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/4/2026LGVNLongeveron HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.004/21/2026LGVNLongeveron Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PEPGPepGen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026FTLFFitLife Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M4.30N/AN/A$9.07 per share0.08FTLFFitLife Brands$81.46M1.26$1.16 per share9.44$4.65 per share2.35LGVNLongeveron$1.20M20.90N/AN/A$0.25 per share3.22PEPGPepGenN/AN/AN/AN/A$2.14 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/AFTLFFitLife Brands$6.33M$0.6018.119.52N/A6.64%18.31%8.21%N/ALGVNLongeveron-$22.70M-$1.13N/AN/AN/A-1,844.49%-202.41%-140.67%8/12/2026 (Estimated)PEPGPepGen-$89.65M-$1.75N/AN/AN/AN/A-59.89%-49.62%8/6/2026 (Estimated)Latest LGVN, FTLF, PEPG, and AIFC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/14/2026Q1 2026FTLFFitLife Brands$0.14$0.17+$0.03$0.17N/A$25.33 million5/13/2026Q1 2026LGVNLongeveron-$0.19-$0.19N/A-$0.19$0.33 million$0.40 million5/12/2026Q1 2026PEPGPepGen-$0.31-$0.26+$0.05-$0.26N/AN/A4/11/2026Q4 2025AIFCALT5 SigmaN/A-$6.19N/A-$6.19N/A$5.37 million3/17/2026Q4 2025LGVNLongeveron-$0.42-$0.22+$0.20-$0.22$0.11 million$0.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/AFTLFFitLife BrandsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82FTLFFitLife Brands0.781.520.49LGVNLongeveron0.053.883.88PEPGPepGenN/A14.9814.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%FTLFFitLife Brands2.32%LGVNLongeveron10.01%PEPGPepGen58.01%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%FTLFFitLife Brands61.40%LGVNLongeveron7.42%PEPGPepGen1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/AFTLFFitLife Brands209.39 million3.63 millionNot OptionableLGVNLongeveron2031.15 million28.84 millionNot OptionablePEPGPepGen3069.17 million68.27 millionNot OptionableLGVN, FTLF, PEPG, and AIFC HeadlinesRecent News About These CompaniesWall Street Zen Upgrades PepGen (NASDAQ:PEPG) to "Hold"June 7, 2026 | americanbankingnews.comPepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 20, 2026 | zacks.com10 Best NASDAQ Stocks Under $5 to Buy Right NowMay 18, 2026 | insidermonkey.comIs PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now?May 18, 2026 | finance.yahoo.comPepGen (PEPG) Upgraded to Buy: Here's What You Should KnowMay 13, 2026 | zacks.comPepGen Reports First Quarter 2026 Financial Results and Recent Corporate HighlightsMay 12, 2026 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGMay 7, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 30, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 28, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)April 26, 2026 | theglobeandmail.comStifel Nicolaus Sticks to Its Buy Rating for PepGen Inc. (PEPG)April 26, 2026 | theglobeandmail.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 16, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 14, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 9, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 7, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPGApril 2, 2026 | prnewswire.comPepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some ReliefMarch 31, 2026 | seekingalpha.comPepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting DiseaseMarch 31, 2026 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLGVN, FTLF, PEPG, and AIFC Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.76 +0.10 (+14.81%) As of 01:15 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.FitLife Brands NASDAQ:FTLF$10.94 -0.07 (-0.61%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Longeveron NASDAQ:LGVN$0.80 +0.02 (+2.86%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.PepGen NASDAQ:PEPG$1.52 +0.05 (+3.67%) As of 01:34 PM Eastern This is a fair market value price provided by Massive. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Meta to Follow Alphabet's Footsteps? What an Equity Raise Could Mean Viasat's Orbiting Profits: Space Force Jackpot? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
